| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911242 | Lung Cancer | 2013 | 7 Pages |
Abstract
Mucin was less frequent in the cross-validation group due to its higher percentage of squamous cell carcinomas. The negative impact of mucin was confirmed for DFS but not for OS. Mucin expression was not predictive of overall survival benefit from adjuvant chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stephen L. Graziano, Benjamin Lacas, Robin Vollmer, Robert Kratzke, Helmut Popper, Martin Filipits, Lesley Seymour, Frances A. Shepherd, Rafael Rosell, Anne Sophie Veillard, Miquel Taron, Jean-Pierre Pignon,